Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Small Cell Lung Cancer
Recurrent small cell lung cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the chest, central nervous system, or in other parts of the body.
Oral Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Endometrial Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Risks of Endometrial Cancer Screening
Screening tests have risks.Decisions about screening tests can be difficult. Not all screening tests are helpful and most have risks. Before having any screening test, you may want to discuss the test with your doctor. It is important to know the risks of the test and whether it has been proven to reduce the risk of dying from cancer.The risks of endometrial cancer screening tests include the following: Finding endometrial cancer may not improve health or help a woman live longer. Screening may not improve your health or help you live longer if you have advanced endometrial cancer or if it has already spread to other places in your body. Some cancers never cause symptoms or become life-threatening, but if found by a screening test, the cancer may be treated. It is not known if treatment of these cancers would help you live longer than if no treatment were given, and treatments for cancer may have serious side effects.False-negative test results can occur.Screening test results may
Gallbladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Unresectable, Recurrent, or Metastatic Gallbladder Cancer
These patients are not curable. Significant symptomatic benefit can often be achieved with relief of biliary obstruction. A few patients have very slow-growing tumors and may live several years. Patients with unresectable, recurrent, or metastatic gallbladder cancer should be considered for inclusion in clinical trials whenever possible. Information about ongoing clinical trials is available from the NCI Web site.Treatment options:Relief of biliary obstruction is warranted when symptoms such as pruritus and hepatic dysfunction outweigh other symptoms from the cancer. The preferred approach is percutaneous transhepatic drainage or endoscopically placed stents; surgical bypass may be appropriate when these approaches are infeasible. Palliative radiation therapy after biliary drainage may be beneficial, and patients may be candidates for inclusion in clinical trials that explore ways to improve the effects of radiation therapy with various radiation sensitizers such as hyperthermia,
Pituitary Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000579645-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Pituitary Tumors Treatment
Skin Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Changes to This Summary (07 / 25 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of the EvidenceAdded text to state that the current evidence indicates that sunscreen application as practiced in the general population shows no clear association with reduced risk of melanocytic nevi or melanoma.This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Transitional Care Planning (PDQ®): Supportive care - Health Professional Information [NCI] - Comprehensive Biopsychosocial Assessment
Successful discharge planning and planning for transitions begin with an adequate biopsychosocial assessment of the patient and family. This assessment should recognize patients who need help as well as those who are not getting enough help.[2,3] The following areas require assessment: Physiological:Type of cancer.Functional status.Symptom profile.Disease stage.Disease status (new diagnosis, recurrent, progressive, or remission).Smoking status. (Refer to the PDQ summary on Smoking in Cancer Care for more information.)Nutrition status. (Refer to the PDQ summary on Nutrition in Cancer Care for more information.)Metastasis.Impact of current treatment.Treatment options for the future.Impairment, disability, and/or handicap; or functional independence.Demographics of patient and caregiver:Age, marital status, parental status, and education/occupation.Sex.Length of hospital stay.Primary language.Cultural background; relevant beliefs and practices.Physical barriers to
Gallbladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Gastric Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Stage 0 (Carcinoma in Situ)Treatment of stage 0 is usually surgery (total or subtotal gastrectomy).Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage 0 gastric cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.Stage I Gastric CancerTreatment of stage I gastric cancer may include the following:Surgery (total or subtotal gastrectomy).Surgery (total or subtotal gastrectomy) followed by chemoradiation therapy.A clinical trial of chemoradiation therapy given before surgery.Check for U.S.
Gastric Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support